AR127700A1 - Prueba de disolución - Google Patents
Prueba de disoluciónInfo
- Publication number
- AR127700A1 AR127700A1 ARP220103162A ARP220103162A AR127700A1 AR 127700 A1 AR127700 A1 AR 127700A1 AR P220103162 A ARP220103162 A AR P220103162A AR P220103162 A ARP220103162 A AR P220103162A AR 127700 A1 AR127700 A1 AR 127700A1
- Authority
- AR
- Argentina
- Prior art keywords
- samples
- evaluation
- relates
- present
- dissolution test
- Prior art date
Links
- 238000007922 dissolution test Methods 0.000 title 1
- 238000011156 evaluation Methods 0.000 abstract 3
- 238000004090 dissolution Methods 0.000 abstract 2
- YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 abstract 2
- 229960002814 rilpivirine Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012736 aqueous medium Substances 0.000 abstract 1
- 238000005259 measurement Methods 0.000 abstract 1
- 239000011859 microparticle Substances 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 238000003908 quality control method Methods 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Sampling And Sample Adjustment (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a la evaluación de muestras que comprenden rilpivirina o una sal farmacéuticamente aceptable de esta en forma de micro- o nanopartículas, tales como suspensiones, y a la medición de la disolución de la rilpivirina o una sal farmacéuticamente aceptable de esta en un medio acuoso. La presente invención también se refiere a la evaluación del control de calidad de dichas muestras y a la entrega de lotes que comprenden dichas muestras para uso farmacéutico. La presente invención también se refiere a un medio para su uso en la evaluación de la disolución.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2021/072453 WO2022109555A1 (en) | 2020-11-17 | 2021-11-17 | Treatment or prevention of hiv infection |
| US202263342834P | 2022-05-17 | 2022-05-17 | |
| EP22173914 | 2022-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127700A1 true AR127700A1 (es) | 2024-02-21 |
Family
ID=84421043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220103162A AR127700A1 (es) | 2021-11-17 | 2022-11-16 | Prueba de disolución |
Country Status (4)
| Country | Link |
|---|---|
| AR (1) | AR127700A1 (es) |
| CA (1) | CA3234763A1 (es) |
| TW (1) | TW202333725A (es) |
| WO (1) | WO2023088964A1 (es) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| BR122020011487B1 (pt) | 2006-06-23 | 2024-02-20 | Janssen Sciences Ireland Uc | Composição farmacêutica compreendendo micro ou nanopartículas do composto tmc278 e seu processo de preparação |
-
2022
- 2022-11-16 CA CA3234763A patent/CA3234763A1/en active Pending
- 2022-11-16 TW TW111143802A patent/TW202333725A/zh unknown
- 2022-11-16 WO PCT/EP2022/082130 patent/WO2023088964A1/en active Application Filing
- 2022-11-16 AR ARP220103162A patent/AR127700A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023088964A1 (en) | 2023-05-25 |
| TW202333725A (zh) | 2023-09-01 |
| CA3234763A1 (en) | 2023-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Firdessa et al. | Identification of multiple cellular uptake pathways of polystyrene nanoparticles and factors affecting the uptake: Relevance for drug delivery systems | |
| Zhou et al. | Elucidating the endocytosis, intracellular trafficking, and exocytosis of carbon dots in neural cells | |
| Moreau et al. | Autophagosome precursor maturation requires homotypic fusion | |
| Jiang et al. | Functional graphene oxide as cancer-targeted drug delivery system to selectively induce oesophageal cancer cell apoptosis | |
| NI201600138A (es) | Nanopartículas terapéuticas que comprenden un agente terapéutico, y metodos para su elaboración y uso | |
| PH12018501400A1 (en) | Wash-durable, fluid absorbent substrate with antimicrobial properties and/or improved washability, and hygiene product such as reusable sanitary napkin | |
| BR112017016311A2 (pt) | derivados de 9h-pirrolo-dipiridina | |
| BR112016009071A8 (pt) | Composição cosmética em forma de nanofibras, método de produção de composição e uso | |
| BR112018006680A2 (pt) | supressor contendo nanomaterial conjugado por polímero solúvel em água e uso do mesmo | |
| BR112017004141B8 (pt) | Agente de imagemamento e seu uso | |
| BR112017020689A2 (pt) | imunoconjugados em nanopartículas | |
| Fede et al. | The toxicity outcome of silica nanoparticles (Ludox®) is influenced by testing techniques and treatment modalities | |
| CO2017002400A2 (es) | Composiciones y métodos para detección de proteína smn en un sujeto | |
| Jensen et al. | Lipogels: surface-adherent composite hydrogels assembled from poly (vinyl alcohol) and liposomes | |
| UY35275A (es) | Derivados de aminopirazina | |
| WO2016040891A3 (en) | In vitro compositions comprising human sample and amyloid targeting agent | |
| BR112013001296A2 (pt) | composições farmacêuticas e respectivo uso e métodos de tratamento de vertigem de diferentes origens, cinetose e distonia vascular vegetativa | |
| Papadakis et al. | Axl promotes cutaneous squamous cell carcinoma survival through negative regulation of pro-apoptotic Bcl-2 family members | |
| CL2009001076A1 (es) | Nanoparticulas que comprende una sustancia formadora de particulas y una proteina; composicion que comprende dichas nanoparticulas; procedimiento para suministrar una proteina a traves de la membrana hematoencefalica; uso de la composicion para profilaxis o tratar enfermedades del sistema nervioso central. | |
| BR112017010037A2 (pt) | acabamento livre de tensoativo sintético, folha tendo acabamento livre de tensoativo sintético, artigos tendo folha com acabamento livre de tensoativo sintético e métodos relacionados | |
| UY32520A (es) | Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides | |
| Weir et al. | Host cell virus entry mediated by Australian bat lyssavirus G envelope glycoprotein occurs through a clathrin-mediated endocytic pathway that requires actin and Rab5 | |
| BR112014032583A8 (pt) | forma farmacêutica para liberação prolongada de substâncias ativas e seu processo de produção | |
| AR127700A1 (es) | Prueba de disolución | |
| UY35824A (es) | Preparación farmacéutica y forma de su producción y uso |